- Biotech Networks Speed Networking: San Francisco Bay Area October 25th 2023
- Biotech Networks Event: Speed Networking in San Francisco April 24th 2023
- Aiolos Bio launches with $245M Series A, chasing one of asthma’s hottest targets
- Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
- Biotech Networks Speed Networking: San Francisco & JPM January 8th 2024
- AbbVie fully ditches I-Mab’s CD47 drug after initial 2022 pullback from $1B+ bet
- CRISPR unicorn Mammoth Biosciences shifts from diagnostics with layoffs
- This biotech went public 3 years ago at $14 per share. Here’s how its stock cratered to 27 cents
- Early-stage cancer drug company to cut 70% of workforce, halt programs
- Scoop: Just months after Sanofi AI deal, Atomwise laid off 30% of staffers amid ‘strategic shift’
- South San Francisco cell therapy startup raises $255 million
- Scoop: Metagenomi is preparing for a fall IPO and is working with JP Morgan
- Charles River Laboratories to lay off 55 employees
- Regel Therapeutics details its proprietary T3 platform and development pipeline on its newly launched website, expands its Board of Directors and announces its Scientific Advisory Board.
- First AI-designed drugs fall short in the clinic, following years of hype
- STAT+: Gene therapy is in crisis. For nine hours, the field’s leading minds looked for a solution
- ViiV drives new corporate coalition including Uber, Tinder and Walmart, aimed at ending HIV
- Biotech startup with connections to Genentech, Gilead lands $245M Series A
- East Bay biotech raised about $800M in 4 years. Now it’s cutting at least 10% of jobs
- Versant’s new immunology biotech Santa Ana Bio snags Series A with GV, TPG partners on board
- ESMO embargo break leads cancer conference to release data for Bristol Myers, J&J, Novartis, Astra
- Biotech company to shutter Peninsula HQ, restructure, cut 162 jobs
- Gilead stops another CD47 study, this time in acute myeloid leukemia
- FibroGen limits rare-disease drug’s access after clinical trial failure. Some parents say it was saving their kids’ lives
- STAT+: As Ginkgo stock sinks, CEO Jason Kelly tries to win over drugmakers in San Francisco
- CCRM Fertility Acquires The New Hope Center for Reproductive Medicine
- BridgeBio inks $250M PIPE two months after PhIII heart pill win
- Illumina to cut real estate, jobs on Peninsula as it looks at ‘options’ after boardroom battle
- Gilead aims for 2026 opening for new cancer research center
- Twist Bioscience Appoints Chet Gandhi as Chief Information Officer
- Thousands of gene and cell therapies are inundating FDA reviewers as the agency tries to keep up
- STAT+: Still hoping for looser FDA rules, Regeneron says it will test durable antibody for Covid
- Fujifilm Diosynth names Lars Petersen to replace Martin Meeson as CEO
- Former partner aims to extend Amyris bankruptcy before it toggles to a sale
- Genentech CEO Alexander Hardy resigns effective immediately to replace Jean-Jacques Bienaimé as CEO at BioMarin
- ExcepGen Emerges From Stealth with New Funding for its Nucleic Acid Therapeutics Platform
- How humbled drug developer BridgeBio is plotting a comeback
- What we’re seeing at JPM so far: Upcoming BD moves, pipeline updates and more
- STAT+: How Mindstrong’s rush to roll out a ‘smoke alarm’ for mental illness led to its downfall
- ‘As the market has turned’: Enveda secures $68M to move revised pipeline into the clinic in 2023
- STAT+: In Silicon Valley, a venture capital firm gives health tech startups a crash course in getting paid
- S.F. biotech inches closer to potential HIV cure with key move by FDA
- Charles River Labs to shut 1 of 3 facilities in South San Francisco
- STAT+: ‘It was my call’: Stanford president defends decision not to correct key paper in misconduct investigation
- STAT+: Carbon Health blasts a major insurer in rare public dispute over coverage
- BioMarin makes $41M+ expansion to Irish facility
- STAT+: After four years of big talk, mega startup Sana prepares to deliver some data
- Scoop: Blade Therapeutics CEO, CFO appear to depart amid ‘transition’ after nixed SPAC
- Acurex Biosciences to Present at the Michael J. Fox Foundation Parkinson’s Disease Therapeutics Conference
- Rare disease trials can’t find enough patients. It’s forcing the FDA to rethink its approach
- MapLight raises $225M in bid to make better schizophrenia drug than pathfinder Karuna
- Here’s why Emerson Collective spun off its Reed Jobs-headed health investing arm into Yosemite Management
- How a Peninsula biotech turned its psoriasis drugs into a $2.4 billion acquisition
- CipherHealth Notches Consecutive Wins from Stevie Awards and MedTech Breakthrough Awards
- Cargo Therapeutics files for IPO, aiming to raise money to fund cell therapy ambitions
- Peninsula biotech lands $55M as Big Pharma exercises option on Alzheimer’s drug
- Arcus, Gilead drop A2R inhibitor in prostate cancer after glimpsing early data
- UCSF researchers’ startup aims to stop allergies — starting with babies’ guts
- Gene therapy company pulls in another $150M to continue scale-up
- Vivalink’s Biometrics Data Platform Supports UCSF Clinical Trial for Hypertrophic Cardiomyopathy (HCM)
- Gilead sues former CFO of Immunomedics to claw back $4 million
- 280 Bio receives IND approval from the FDA for YL-17231
- FDA warns Genentech clinical investigator working on preventive flu antiviral trial
- Bristol Myers cuts mid-stage NASH, anti-TIGIT programs
- IRA impact on biopharma: Latest SEC disclosures range from unknown to negative
- Arcus deprioritizes Gilead-partnered drug in prostate cancer, the latest hiccup in $1.6B collaboration
- A gene therapy for Alzheimer’s Disease? North Bay rare disease pioneer hopes to spin out company to do it
- Pragma Bio Secures $10M From The Venture Collective, Merck Global Health Innovation Fund, Viking Global, and CJ Investments To Expand Its Proprietary Technology Platform To Discover Novel Medicines
- Headlands Research Acquires AMCR Institute, Adding Medical Device Expertise to the Clinical Research Site Network
- STAT+: No more ‘playing God’: How the longevity field is trying to recast its work as serious science
- GSK’s ViiV to lean on long-acting HIV portfolio ahead of dolutegravir patent expiration
- STAT+: Regeneron’s George Yancopoulos admits some regret, but ‘I don’t apologize’
- Biotech supplier Abcam is closing its 2nd Bay Area location this year and cutting 43 more workers
- Emerson Collective Health Spins Off to Form New Investment Fund, Yosemite; Announces First Close of Oversubscribed $200M+ Fund to Accelerate Transformative Cancer Ventures
- Sana lays off staff as cell therapy biotech awaits first clinical data
- Bay Area Biotech Landlords Sweeten Deals For Tenants As Wave Of Available Space Grows
- STAT+: Medicare Advantage-focused Oak Street, Agilon Health chart out growth at J.P. Morgan
- Why we need rescue robots to seem brave and vulnerable
- Aiming for ‘the year of Roctavian,’ BioMarin awaits FDA decision on hemophilia gene therapy
- Meet 20 women leaders reshaping biopharma in 2023
- ‘Two-Eyed Seeing’ off the California coast
- Amgen extends autoimmune pact with small Michigan biotech
- Alderson Convalescent Hospital in Woodland sold to Los Angeles group for $11.5 million
- Evotec’s CNS deal with Bristol Myers gets $50M infusion and eight-year extension
- While dollars continue to flow into biotech, companies cut more jobs
- Another Eylea threat: Roche expands label for blockbuster eye drug Vabysmo
- Pyramid inks TROP2 pact with China biotech to follow suit of Gilead, AstraZeneca-Daiichi Sankyo
- Happiest Minds is among Top 10 India’s Best Workplaces™ in Health & Wellness 2022
- Accuray CyberKnife® and TomoTherapy® Platforms Featured in More Than 55 Abstracts Presented at ESTRO 2023, Reinforcing Systems’ Versatility, Efficiency and Effectiveness
- Stanford president to resign after investigation into scientific papers
- JAMA’s new editor settles in, bringing open access and other changes
- ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
- After first-line approval in DLBCL, debate continues around benefit from Roche’s ADC Polivy
- California Alzheimer’s startup TrueBinding raises more than $50M, lays off workers twice in June
- DNAnexus and BigOmics Analytics Join Forces to Improve Proteomics and Transcriptomics Data Visualization and Interpretation
- Verana Health to Enable Cloud-based Access to its Curated, De-identified Real-World Data Through AWS Data Exchange
- Qylur Intelligent Systems Awarded U.S. Air Force SBIR Phase I Contract, Taps into Dual-Use Autonomous AI Market
- National Organization of Rare Disorders (NORD) Announces 2023 Rare Impact Award Honorees
- Terns Pharmaceuticals CEO bows out for health reasons
- Boston Scientific AGENT™ Drug-Coated Balloon Demonstrates Superiority to Uncoated Balloon Angioplasty in the AGENT IDE Trial
Copyright © 2023 Biotech Networks, LLC
